Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of donepezil and duloxetine represents a drug pairing that has been studied for potential therapeutic benefits, particularly in the treatment of neuropathic pain and potentially in cognitive conditions. Donepezil and duloxetine is a drug combination that works through complementary mechanisms of action. Donepezil is an acetylcholinesterase inhibitor that increases acetylcholine levels in the brain, primarily used for Alzheimer's disease and other forms of dementia[3][6]. Duloxetine is a serotonin and norepinephrine reuptake inhibitor (SNRI) that increases the availability of these neurotransmitters in the central nervous system, commonly used for depression, anxiety disorders, and neuropathic pain[8][9]. When combined, these medications may offer synergistic effects, particularly in the treatment of neuropathic pain. Research suggests that this combination, especially when used with gabapentin, can produce enhanced analgesic effects through the modulation of the bulbospinal-spinal noradrenergic-cholinergic pathway[4][5]. The combination has been investigated in clinical trials for conditions such as diabetic neuropathic pain and failed low back syndrome.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on donepezil + duloxetine.